Who are DFN-15 Dose 1's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Latuda (Lurasidone), Latuda©, NRX-101 Oral Capsule, Vortioxetine tablets, OPC-34712, Phase 1: Aripiprazole.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dfn-15-dose-1.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

DFN-15 Dose 1 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DFN-15 Dose 1 (DFN-15 Dose 1) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: 5-HT7 receptor antagonist. Area: Psychiatry/Neurology.

phase 2 5-HT7 receptor antagonist 5-HT7 receptor Psychiatry/Neurology Small molecule Live · refreshed every 30 min

Target snapshot

DFN-15 Dose 1 (DFN-15 Dose 1) — Dr. Reddy's Laboratories Limited. DFN-15 is a selective serotonin 5-HT7 receptor antagonist designed to modulate serotonergic neurotransmission.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
DFN-15 Dose 1 TARGET	DFN-15 Dose 1	Dr. Reddy's Laboratories Limited	phase 2	5-HT7 receptor antagonist	5-HT7 receptor
Latuda (Lurasidone)	Latuda (Lurasidone)	Massachusetts General Hospital	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT7 receptor
Latuda©	Latuda©	University of North Carolina, Chapel Hill	marketed	Atypical antipsychotic	Dopamine D2 receptor, serotonin 5-HT7 receptor, serotonin 5-HT1A receptor
NRX-101 Oral Capsule	NRX-101 Oral Capsule	NeuroRx, Inc.	phase 3	Fixed-dose combination (NMDA receptor modulator + atypical antipsychotic)	NMDA receptor (d-cycloserine component); dopamine D2 receptor and serotonin 5-HT7 receptor (lurasidone component)
Vortioxetine tablets	Vortioxetine tablets	Takeda	phase 3	Serotonin modulator and stimulator	5-HT3 receptor, 5-HT1A receptor, 5-HT7 receptor, norepinephrine transporter
OPC-34712	OPC-34712	Otsuka Pharmaceutical Development & Commercialization, Inc.	phase 3	5-HT7 receptor antagonist	5-HT7 receptor
Phase 1: Aripiprazole	Phase 1: Aripiprazole	Shanghai Mental Health Center	phase 3	Atypical antipsychotic	Dopamine D2/D3 receptor (partial agonist); serotonin 5-HT1A and 5-HT7 receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (5-HT7 receptor antagonist class)

Otsuka Pharmaceutical Development & Commercialization, Inc. · 2 drugs in this class
Dr. Reddy's Laboratories Limited · 1 drug in this class
Eli Lilly and Company · 1 drug in this class
Neumora Therapeutics, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DFN-15 Dose 1 — Competitive Intelligence Brief. https://druglandscape.com/ci/dfn-15-dose-1. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing